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Abstract: Adults with Down Syndrome (DS) are at higher risk for severe outcomes of coronavirus
disease 2019 (COVID-19) than the general population, but evidence is required to understand the
risks for children with DS, which is necessary to inform COVID-19 shielding advice and vaccination
priorities. We aimed to determine the epidemiological and clinical characteristics of COVID-19
in children with DS. Using data from an international survey obtained from a range of countries
and control data from the United States, we compared the prevalence of symptoms and medical
complications and risk factors for severe outcomes between DS and non-DS paediatric populations
with COVID-19. Hospitalised COVID-19 patients <18 years with DS had a higher incidence of
respiratory symptoms, fever, and several medical complications from COVID-19 than control patients
without DS <18 years. Older age, obesity, and epilepsy were significant risk factors for hospitalisation
among paediatric COVID-19 patients with DS, and age and thyroid disorder were significant risk
factors for acute respiratory distress syndrome. Mortality rates were low in all paediatric COVID-19
patients (with and without DS), contrasting with previous findings in adults with DS (who exhibit
higher mortality than those without DS). Children with DS are at increased risk for more severe
presentations of COVID-19. Efforts should be made to ensure the comprehensive and early detection
of COVID-19 in this population and to identify children with DS who present comorbidities that
pose a risk for a severe course of COVID-19. Our results emphasize the importance of vaccinating
children with DS as soon as they become eligible.
Keywords: COVID-19; Down Syndrome; paediatrics
1. Introduction
Down Syndrome (DS) is associated with genetic factors and medical comorbidities
that may lead to increased vulnerability to a severe course of coronavirus disease 2019
(COVID-19)—the illness caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2). Immune dysregulation among individuals with DS increases vulnerability
to viral infections, while anatomical airway features increase the vulnerability to respiratory
illnesses [1–3]. Respiratory illnesses are a major cause of premature mortality in people
with DS [4,5], and children with DS show a high susceptibility to recurrent respiratory
infections [6]. Indeed, many non-respiratory comorbidities of DS, such as obesity, diabetes,
or heart conditions, are known risk factors for morbidity and mortality from COVID-19 in
the general population [2,3].
Unlike in the adult population, limited data are available on children with DS and
COVID-19. Some reports have highlighted a few cases of children who had one or more
comorbidities, including cardiovascular anomalies, obesity, and/or obstructive sleep ap-
noea [7,8], but these reports were based on only 55 and 4 participants, respectively.
This study aims to describe the epidemiological and clinical characteristics of COVID-
19 in children with DS, including risk factors for a severe course of illness, compared to those
in the general paediatric population. In this study, severe COVID-19 is assessed holistically
by comparing the rate of hospitalisation (including the rate of mechanical ventilation
and intensive care unit (ICU) admission), acute respiratory distress syndrome (ARDS),
and shortness of breath, in addition to mortality. Due to the limited data availability,
control data (children with COVID-19 from the general population) were only available
from the US. As our data on children with DS were drawn from countries with varying
income levels, we explored the differential course of paediatric COVID-19 cases from
low-to-middle-income countries (LMICs) and from high-income countries (HICs) [9].
2. Materials and Methods
2.1. T21RS DS Survey
We used data from the Trisomy 21 Research Society (T21RS) international survey,
the largest survey of individuals with DS who had COVID-19. Caregivers and clinicians
caring for people with DS provided information about the symptoms, outcomes, and
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existing health conditions of COVID-19 patients using an anonymous online format. The
clinician surveys also asked about COVID-related treatments and medical complications.
From all paediatric cases under 18 years of age reported to T21RS from 9 April 2020 and
22 October 2020, after excluding patients with missing relevant information such as age,
gender, or clinical information, our sample included 328 paediatric COVID-19 patients
with DS. We excluded duplicated participants identified based on age, gender, and country,
and other specific demographics. Because this study relies on data from the first wave
of the pandemic, 29% (95/328) of the paediatric cases reported in the T21RS dataset had
not been tested for COVID-19 but were symptomatic (Table A1). For validation purposes,
we further compared the data to those generated from participants who completed the
T21RS survey during a later phase of the pandemic (22 October 2020, to 2 August 2021;
133 additional paediatric COVID-19 patients with DS). Figure A1 shows the distribution of
when COVID-19 patients with DS were entered into the T21RS database.
The survey was implemented through REDCAP [10,11], a survey and database man-
agement system, and was hosted at Emory University. The survey was disseminated
through clinical routes (e.g., Down Syndrome medical interest group listservs and health
service providers), Down Syndrome associations in the US, India, Spain, UK, France,
Italy, Germany, Brazil, and Spanish-speaking Latin America, and DS registries (e.g., NIH
DS-Connect®), as well as via the T21RS website. Each participating institution obtained
IRB/ethics approval (Institutional Review Board Statement). The study was performed
according to the Declaration of Helsinki and national guidelines and regulations for data
privacy, and all participants who completed the questionnaires provided informed con-
sent. All data were anonymised according to good clinical practice guidelines and data
protection regulations.
2.2. US COVID-NET Comparison Data
To contrast the COVID-19-related signs, symptoms, and medical complications with
those observed in the general population, we compared the hospitalised T21RS DS cases
to published results from paediatric cases reported by the COVID-19–Associated Hospi-
talisation Surveillance Network (COVID-NET). COVID-NET is a US population-based
surveillance system that collects data on laboratory-confirmed COVID-19–associated hospi-
talisations [12]. From 1 March to 25 July 2020, 576 hospitalised paediatric COVID-19 cases
were reported to the COVID-NET10.
2.3. Statistical Analyses
We used descriptive statistics to show the demographic information, outcomes, and
COVID-19 symptoms and comorbidities of the participants included in our analyses.
Categorical data were described as frequencies (percentages), and quantitative variables
were provided as the mean (SD) or median (IQR). We used Fisher’s exact tests to compare
characteristics of the COVID-NET controls to those observed in COVID-19 patients with DS.
Due to limited data availability, we only had control data from the US (COVID-NET). To
detect possible country-specific differences in the healthcare system and access to hospitals,
we stratified the COVID-19 patients with DS from the T21RS survey by the income level
of the country of residence. Countries were categorised as HICs (USA, Canada, Western
Europe, Argentina, Australia) or LMICs (Brazil, India, Iran, Egypt, Belarus, South Africa,
Mexico, Costa Rica, Bangladesh, Nepal) based on the World Bank income classification
system [13].
To identify risk factors associated with adverse outcomes of COVID-19 in children
with DS, we estimated associations between potential risk factors and admission to hospital,
diagnosis of acute respiratory distress syndrome (ARDS), and the presence of shortness
of breath using logistic regression analyses. All association analyses were restricted to
symptomatic COVID-19 cases from the T21RS survey data, controlling for data source
(caregiver versus clinician survey), living situation, level of intellectual disability, age,
gender, and country of residence.
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All data analyses were conducted using R (version 4.0.0).
3. Results
This retrospective cohort study included 328 paediatric patients <18 years of age
with DS and COVID-19. Of the individuals for whom we had relevant information, 38.8%
(127/325) were hospitalised. The mean age was 9.55 (SD = 5.24) years (8.47 (SD = 4.99) for
non-hospitalised and 11.37 (SD = 5.07) for hospitalised respondents. Of the patients for
whom country information was available, 42.9% (137/319) were from India, 17.6% (56/319)
were from Brazil, 11.3% (36/319) were from the UK, 9.4% (30/319) were from the USA,
3.8% (12/319) were from Spain, and 15% (48/319) were from other countries (Table 1). Note
that some information was missing for certain patients; percentages reflect the portion
of individuals for whom data were available. A description of the children’s ethnicities
stratified by country of residence is presented in Table A2. The age distribution was slightly
different between the T21RS individuals with Down Syndrome and the CDC controls
without Down Syndrome (Table A3). The CDC controls involved more newborns <1 year
of age (CDC controls: 27.3%, T21RS: 4.3%), and the proportion of 5–11 year-olds was higher
among the study population with Down Syndrome (CDC controls: 16.8%, T21RS: 36.3%).
The gender distribution was comparable between both studies (CDC controls: 50.7% male,
T21RS: 47.4% male).
Table 1. T21RS study characteristics grouped by hospital admission.
Overall Not Hospitalised Hospitalised
n 328 197 127
Additional information through follow-up (%) # 29 (8.8) 25 (12.7) 4 (3.1)
Country (%)
India 137 (42.9) 52 (27.1) 85 (69.1)
Brazil 56 (17.6) 44 (22.9) 11 (8.9)
United Kingdom 36 (11.3) 28 (14.6) 8 (6.5)
United States 30 (9.4) 22 (11.5) 7 (5.7)
Spain 12 (3.8) 9 (4.7) 3 (2.4)
other 48 (15.0) 37 (19.3) 9 (7.3)
Age (mean (SD)) 9.55 (5.24) 8.47 (4.99) 11.37 (5.07)
Male (%) 173 (52.7) 97 (48.5) 74 (58.3)
Ethnicity (%)
South Asian 142 (43.2) 54 (27.4) 88 (69.3)
White 110 (33.4) 89 (44.2) 21 (16.5)
Latin American 31 (9.4) 23 (11.7) 7 (5.5)
Black 6 (1.8) 3 (1.5) 3 (2.4)
Arab 1 (0.3) 1 (0.5) 0 (0.0)
West Asian 1 (0.3) 1 (0.5) 0 (0.0)
Admixed 12 (3.6) 9 (4.6) 3 (2.4)
Unknown 26 (7.9) 19 (9.6) 5 (3.9)
Living situation (%)
Living at home with family 304 (98.1) 190 (97.9) 110 (98.2)
Living alone with support 1 (0.3) 0 (0.0) 1 (0.9)
Small group home with support 2 (0.6) 2 (1.0) 0 (0.0)
Residential care facility 2 (0.6) 1 (0.5) 1 (0.9)
Other 1 (0.3) 1 (0.5) 0 (0.0)
Type of trisomy 21 (%)
Full/standard 274 (88.4) 167 (87.9) 105 (89.7)
Mosaic 29 (9.4) 17 (8.9) 11 (9.4)
Partial trisomy 2 (0.6) 2 (1.0) 0 (0.0)
Translocation 5 (1.6) 4 (2.1) 1 (0.9)
Level of intellectual disability (%)
Borderline/normal/mild 83 (30.0) 59 (37.1) 23 (20.2)
Moderate 172 (62.1) 91 (57.2) 78 (68.4)
Severe/Profound 22 (7.9) 9 (5.7) 13 (11.4)
Admitted to hospital (%) 127 (39.2) 0 (0.0) 127 (100.0)
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Table 1. Cont.
Overall Not Hospitalised Hospitalised
Days in hospital (mean (SD)) * 11.03 (5.18) NA 11.03 (5.18)
Admitted to ICU (%) * 48 (38.4) 0 (0) 48 (38.4)
Days in ICU (mean (SD)) * 6.91 (2.52) NA 6.91 (2.52)
Mechanical ventilation (%) * 28 (16.1) 0 (0.0) 28 (24.8)
Clinical situation at last evaluation (%)
Currently in hospital with symptoms 38 (12.5) 0 (0.0) 37 (31.4)
Died 4 (1.3) 0 (0.0) 4 (3.4)
Not currently in hospital but with symptoms 45 (14.8) 34 (18.6) 10 (8.5)
Other 12 (3.9) 9 (4.9) 3 (2.5)
Recovered from COVID-19 197 (64.8) 132 (71.1) 64 (54.2)
Tested positive but still no symptoms 8 (2.6) 8 (4.4) 0 (0.0)
* Only answered if admitted to hospital; # Information that was missing in the original report was imputed by information provided
through a follow-up survey (clinician follow-up for the family survey and family follow-up for the clinician survey, see methods for more
details); percentages were calculated after excluding missing information. NA: not applicable.
Among children with DS and COVID-19, hospitalised children had more respiratory
signs and symptoms than those that were not hospitalised (Table A4). Among those
hospitalised with COVID-19, children with DS had significantly higher rates of cough
(53.7% vs. 29.5% in controls), fever (94.3% vs. 54% in controls), nasal signs/congestion
(65.0% vs. 23.7% in controls), and shortness of breath (60.2% vs. 22.3% in controls) than the
control group (Table 2). Hospitalised children with DS did not experience a significantly
different prevalence of abdominal symptoms in comparison to the control group.
Medical complications were more prevalent among children with DS than among con-
trols. Children with DS had significantly higher rates of pneumonia (36.9% vs. 11.1% con-
trols), ARDS (32.8% DS vs. 1.9% controls), and acute renal failure (17.3% DS vs. 2.9% con-
trols). There was no significant difference in the prevalence of Multisystem Inflammatory
Syndrome between COVID-19 patients with and without DS.
Children with DS had similar rates of ICU admission (38.4% DS vs. 33.2% controls)
but were more often put on mechanical ventilation (24.8% DS vs. 5.8% controls). Hospi-
talised patients with DS had a higher mortality rate compared with controls (5.0% DS vs.
0.5% controls), but all deaths occurred among children from LMIC.
Participants completing the T21RS survey during a later phase of the pandemic
(22 October to 2 August 2021; n = 133) included fewer hospitalised cases (25 (20%)),
but among those who were hospitalised, proportions of ICU admissions and medical
complications were similar to individuals with DS from the earlier phases of the pandemic
(Tables A5 and A6).
Next, we examined potential risk factors for severe COVID-19 (shortness of breath,
hospitalisation, and ARDS) among COVID-19 patients with DS. Rates of hospitalisation
by age group and country income category can be found in Figure 1. A description of the
prevalence of comorbidities is provided in Table A7. Older age (OR 1.75 for 5 additional
years [1.37–2.23]), obesity (OR 2.27 [1.12–4.59]) and epilepsy (OR 3.97 [1.65–9.58]) were
all significant risk factors for hospitalisation among COVID-19 patients with DS (Figure 2
and Table A8); older age (OR 2.29 for 5 additional years [1.26–4.15]) and thyroid disorder
(OR 3.40 [1.03–11.9]) were significant risk factors for ARDS; and older age (OR 1.31 for 5
additional years [1.05–1.63]) was a significant risk factor for shortness of breath.
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Table 2. Severity of COVID-19 among hospitalised individuals with and without DS stratified by high-income and low to
middle-income countries.
A. Signs and Symptoms Related to COVID-19






















Cough, n (%) 66 (29.5) 224 66 (53.7) 123 0.005 19 (82.6) 23 <0.001 47 (47.0) 100 0.003
Fever, n (%) 121(54.0) 224
116




53 (23.7) 224 80 (65.0) 123 <0.001 13 (56.5) 23 0.002 67 (67.0) 100 <0.001
Shortness of
breath, n (%) 50 (22.3) 224 74 (60.2) 123 <0.001 18 (78.3) 23 <0.001 56 (56.0) 100 <0.001
Abdominal
pain, n (%) 42 (18.8) 224 23 (18.7) 123 1 3 (13.0) 23 0.776 20 (20.0) 100 0.879
Vomiting/
nausea, n (%) 69 (30.8) 224 23 (18.7) 123 0.063 3 (13.0) 23 0.092 20 (20.0) 100 0.059
Diarrhoea, n
(%) 27 (12.1) 224 18 (14.6) 123 0.621 6 (26.1) 23 0.098 12 (12.0) 100 1




























12 (5.8) 207 28 (24.8) 113 <0.001 3 (14.3) 21 0.149 25 (27.2) 92 <0.001
Death, n (%) 1 (0.5) 208 4 (5.0) 80 0.025 0 (0.0) 20 1 4 (6.7) 60 <0.001



































9 (10.8) 83 1 (2.2) 46 0.164 1 (33.3) 3 0.361 0 (0.0) 43 0.057
1 T21RS survey: this sign refers to “nasal signs” rather than nasal congestion. 2 T21RS survey: medical complications were only recorded in
surveys answered by clinicians.
The pandemic has posed challenges to healthcare systems globally, and the nature of
the pandemic response may differ depending on the country income status. We stratified
our analysis by country income level to explore this. First, we examined hospitalisation
rates by age group and country income status. Patients with DS from LMICs had a higher
rate of hospitalisation (48.5%) than the sample as a whole (39.0%), except for among
children under 5 years of age. In LMICs, the hospitalisation rate increased with age group,
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consistent with our finding that older age was a risk factor for hospitalisation in our sample
(Figure 2). In HICs, the hospitalisation rate was highest for children under 5, but was
similar for other age groups. The age distribution of hospitalised COVID-19 patients
with DS from HICs versus LMICs was similar during the later phases of the pandemic
(Figure A2).
We compared the symptoms and signs of COVID-19 between the control group
(all hospitalised) and hospitalised children with DS from the HICs and the LMICs. The
prevalence of cough (82.6% in HICs, 46.5% in LMICs, 29.5% in controls), fever (91.3% in
HICs, 95% in LMICs, 54% in controls), nasal congestion (56.5% in HICs, 66.7% in LMICs,
23.7% in controls), and shortness of breath (78.3% in HICs, 55.6% in LMICs, 22.4% in
controls) was significantly higher among children with DS, independent of the country
income status (although the latter was higher in HICs than in LMICs) (Table 2).
On average, children with DS spent more days in the hospital than children from
the general population, independent of their country income status (controls: median of
2.5 days, HICs: median of 8 days, LMICs: median of 10 days). The prevalence of ICU
admission was not different among children with DS from LMICs (43.4%) or HIC (17.4%)
in comparison to controls (33.2%). The prevalence of mechanical ventilation was higher
among children with DS from LMICs (27.2%) than among controls (5.8%) (p < 0.001), but
for children with DS from HICs (14.3%), there was no statistically significant difference
from controls. Lastly, with respect to mortality rates, all deaths among hospitalised children
with DS were from LMICs, leading to estimates of mortality of 6.7% in LMICs, with no
deaths occurring in either controls or children with DS from HICs.
4. Discussion
Previous studies of individuals with DS suggest that, as in the general population,
children do not face the same risk for COVID-19-related mortality as older adults. However,
as severe COVID-19 cannot be assessed by mortality alone, we aimed to evaluate the rate
of several indicators for severe COVID-19 (rate of hospitalisation, use of mechanical venti-
lation and ICU admittance, ARDS, shortness of breath, and mortality) among 328 children
with DS and compare these to 224 children from the general population.
4.1. Hospitalisation and Outcomes
In our study, hospitalised children with DS had significantly higher rates of cough,
fever, nasal signs, and shortness of breath than the control group. This could be interpreted
as a more severe COVID-19, as reflected by the following evidence of poor outcomes:
(1) significantly higher rates of medical complications, including pneumonia, ARDS, and
acute renal failure, and (2) need for mechanical ventilation (24.8% vs. 5.8% in controls).
Mortality rates for children with DS were much lower than for adults with DS, as has also
been reported in general for the paediatric population [12]. We could not examine risk
factors for mortality because there were very few deaths among children with and without
DS. Our results in children with DS are broadly in line with previous works on COVID-19
in adults with DS and with the literature, which suggests that people with DS may be more
susceptible to viral and bacterial infections in terms of symptoms, complications, and a
severe course of illness [4,5,7,14–17].
Risk factors for a severe course of COVID-19 are well-documented for the adult
population with [2] and without DS [18,19], but less so for the paediatric population. In our
sample, many of the documented risk factors for COVID-19 morbidity were found to be
significant, including older age, epilepsy, and obesity. However, several known risk factors
for a severe course of COVID-19 were not found to be statistically significant, including
male sex [20] and chronic lung disease [2]. This may reflect a lack of statistical power and
underscores the need for further study.
Pre-existing epilepsy as a risk factor for severe COVID-19 outcomes has not been
established for those without DS [21,22]. However, there is a consensus that management
of COVID-19 in people with epilepsy compared with those without may be more compli-
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cated, as would be true for those with DS and epilepsy. Some examples of complications
include drug–drug interactions [23], the use of certain epilepsy medications that may
affect the immune system [22], fever related to COVID-19 that may increase the risk of
seizures and lead to increased hospitalisation [21], or increased need for health care or
emergency care that may lead to higher exposure to the virus [21,22]. In those with and
without DS, seizures could be a neurological consequence of COVID-19, as reviewed in
Niazkar et al. [24]. However, further insights into the link between pre-existing epilepsy as
a risk factor for COVID-19 outcomes in DS would benefit from further research. The same
can be said of the risks associated with thyroid disorder—a common comorbidity of DS. It is
possible that infection affected the thyroid function in children with DS, but the mechanism
cannot be determined from the data used in this study. However, both SARS and COVID-19
are known to be associated with thyroid abnormalities in adult patients. SARS patients
have been found to have decreased serum T3, T4, and TSH levels [25]. Thyroid hormone
dysfunction affects the clinical course of COVID-19 as it increases mortality in critical
illnesses such as ARDS, a major complication of COVID-19 [24]. Angiotensin-converting
enzyme 2 (ACE2) requires the transmembrane serine protease 2 (TMPRSS2) to enter cells. In
humans, the TMPRSS2 enzyme is encoded by the TMPRSS2 gene located on chromosome
21 (21q22.3 (OMIM 602060)). TMPRSS2 in turn forms a complex with the ACE2 receptor,
enabling the virus to penetrate the cell surface directly and efficiently [26]. ACE2 and
TMPRSS2 are highly expressed in the thyroid gland [26]. Further investigation is needed to
elucidate whether the impact of SARS-CoV-2 on thyroid function is one of several factors
in the development of ARDS in people, particularly children, with DS and/or primarily
due to the overexpression of TMPRSS2 via a chromosome 21 gene-dose mechanism.
Finally, results varied by country income status for some attributes. The rate of
hospitalisation for children younger than 5 years of age with DS in HICs, and for the US
controls, was particularly high compared to LMICs. This may be a result of neonates
being infected in hospitals immediately after birth [12]. Equally, the higher availability of
resources could allow children under 5 years of age in HICs to be hospitalised for minor
non-COVID-related symptoms or signs of illness in general, regardless of whether or not
they have severe COVID-19. The high rate of hospitalisation in this age group in HICs
(compared with children with DS from LMICs) might not, therefore, be indicative of a more
severe course of illness.
4.2. Implications for Policy and Practice
Our results suggest that children with DS are more likely to develop severe COVID-19
than the general paediatric population. However, it is recognised that a child’s welfare also
needs to be considered. Shielding children may protect them from being infected, but it
will also impact their access to education and interaction with peers and could have an
adverse impact on their development and wellbeing. While this is true for all children, it
is particularly important for children with DS, who are likely to be affected even more by
social isolation and the loss of their daily routine and therapies. These risks must therefore
be balanced with those of protecting children from the infection itself. Parents, health
professionals, and policy makers may therefore wish to consider the risks of infection
to an individual child taking account of their likely exposure to the infection, existing
comorbidities, and family circumstances.
While we found that the risk of severe COVID-19 increased with the presence of
certain comorbidities for our population of interest, we also found that children with
DS are, in general, at increased risk of severe outcomes from this disease. We therefore
recommend, when vaccination is rolled out for paediatric populations, that children with
DS be prioritised.
There are insufficient data currently for a conclusive understanding of the lifelong ef-
fects of COVID-19. Thus, a mild course of the disease may have long-term implications, and
children with DS who experience a less severe course of illness or who are not hospitalised
may still require annual reviews to ensure that their condition has not deteriorated.
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4.3. Limitations and Areas for Future Research
One notable limitation of our study is that control data were only available from
hospitalised [10] paediatric patients in the US, whereas the T21RS study samples came
from many different countries; thus, country-specific differences could have biased our
results. Some countries had more COVID-19 cases than others, health care systems differ
substantially between countries, and some countries experienced a surge in cases later
than others, meaning that they had more time to prepare and develop treatment strategies.
Furthermore, the reason for admission to hospital and ICU could differ between countries.
To address this potential bias, we conducted a comparison stratified by patients from
LMICs and HICs. However, we are aware that there are also substantial differences
between HICs, and we did not have a comparison group from LMICs. Furthermore, the
age distribution of the children with and without DS differed and, as we had access only to
the summary statistics, we could not adjust our association analyses for age. Subsequent
international studies should explore a comparison with controls from a range of countries
when suitable data become available. In addition, most of our cases from LMICs were from
India (137/202), making the generalisation of findings to other LMICs difficult.
When reporting the ethnicity of patients, we used WHO categories, but the way in
which ethnicity was reported varied among countries. We had limited data from Black,
indigenous populations, Asian, and other children representing minority ethnic groups in
HICs and may have overlooked risks unique to those groups.
Another limitation of our study is that most COVID-19 patients from the T21RS and
the US COVID-NET data were reported during the first wave of the pandemic, when
there were few treatment strategies available and mechanical ventilation was often the
only treatment for severe COVID-19 cases with respiratory distress. However, a validation
analysis that included COVID-19 patients with DS from 22 October 2020 to 2 August
2021 showed that hospitalised COVID-19 patients with DS from this later phase of the
pandemic had similar outcomes and severity to those from earlier phases of the pandemic,
strengthening our main conclusions. Another limitation of this study is that not all of
the COVID-19 cases were confirmed by COVID-19-specific laboratory tests. Given that
our survey was launched at the beginning of the pandemic when testing was scarce, we
would have lost 29% of our cases (particularly from Spain, France, and Italy) if we were to
include only individuals with laboratory-confirmed COVID-19. Furthermore, our previous
publication on COVID-19 patients with DS indicated that there was no difference in the
clinical presentation of those who were or were not tested for COVID-19 [2], providing an
added level of confidence for the clinical diagnosis even when laboratory tests were not
reported. In addition, as this study is based on an online survey that was completed by
clinicians as well as family members/caregivers of the individuals with DS, we could not
include any objective laboratory outcome measures. Furthermore, the T21RS survey data
are a convenient sample of individuals with DS who had COVID-19 and not necessarily
representative of all COVID-19 patients with DS. Therefore, the hospitalisation rates (39%
of the children with DS were hospitalised) should be interpreted with caution and are likely
affected by an overrepresentation of patients with severe COVID-19. More attention should
also be paid to non-hospitalised and asymptomatic paediatric COVID-19 patients with DS,
who could experience long-term effects of COVID-19. Thus, future research should aim to
determine if the symptoms of non-hospitalised children with DS differ from those of the
general paediatric population. Because our control data pertained to hospitalised patients
only, this analysis lay beyond the scope of this investigation. Future research must also
investigate the negative psychosocial and developmental impact of being home-bound
during the COVID-19 pandemic on children with DS: emerging survey-based studies are
already underway to document potential outcomes in terms of weight gain, regression,
risk of osteoporosis from lack of exercise, and so forth. Our understanding of COVID-19
will be further enhanced by studying asymptomatic cases: as such, it will be important to
include data from asymptomatic paediatric patients with COVID-19 (and their caregivers
and clinicians) in future surveys now that testing has become more widely available.
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5. Conclusions
Hospitalised children with DS had a higher prevalence of several symptoms of COVID-
19 (cough, fever, nasal signs, shortness of breath) than hospitalised US controls; a higher
prevalence of medical complications from COVID-19 (pneumonia, ARDS, acute renal
failure), particularly among children with DS from LMICs; and were more likely to be
placed on mechanical ventilation. Older age, obesity, and epilepsy were significant risk
factors for hospitalisation; older age and thyroid disorder were significant risk factors for
ARDS; and older age was a significant risk factor for shortness of breath. Efforts should
be made to monitor the health of children and young people with DS during the ongoing
pandemic and to report any COVID-19 signs and symptoms in a timely manner, especially
for those who have comorbidities which are risk factors for severe COVID-19. In addition,
our results emphasise the importance of vaccinating children with DS as soon as they
become eligible.
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2020). COVID-19 cases entered between 22 October 2020 and 2 August 2021 were summarised for validation purposes
(Tables A6 and A7). Upper panel indicates all cases (A) vs. HIC (B) and lower panel denotes all cases (A) vs. LMIC (B).
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Table A1. Proportion of the T21RS analysis sample with COVID-19 symptoms or positive test results.
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Table A2. Ethnicity of the T21RS study participants stratified by country of residence.
Overall India Brazil UK USA Spain Other
n 328 137 56 36 30 12 47
Age (mean (SD)) 9.55 (5.24) 12.71 (3.14) 5.68 (5.26) 8.42 (4.72) 7.33 (5.80) 6.25 (5.50) 8.44 (4.76)
Male (%) 173 (52.7) 61 (44.5) 29 (51.8) 20 (55.6) 18 (60.0) 9 (75.0) 28 (60.9)
Ethnicity (%)
South Asian 142 (43.2) 136 (99.3) 0 (0.0) 2 (5.6) 0 (0.0) 0 (0.0) 3 (6.4)
White 110 (33.4) 0 (0.0) 25 (44.6) 29 (80.6) 21 (70.0) 10 (83.3) 22 (46.8)
Latin American 31 (9.4) 0 (0.0) 20 (35.7) 0 (0.0) 4 (13.3) 0 (0.0) 5 (10.6)
Black 6 (1.8) 0 (0.0) 1 (1.8) 2 (5.6) 3 (10.0) 0 (0.0) 0 (0.0)
Arab 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.1)
West Asian 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.1)
Admixed 12 (3.6) 0 (0.0) 9 (16.1) 1 (2.8) 1 (3.3) 1 (8.3) 0 (0.0)
Unknown 26 (7.9) 1 (0.7) 1 (1.8) 2 (5.6) 1 (3.3) 1 (8.3) 15 (31.9)
Table A3. Study characteristics of T21RS individuals with Down Syndrome (stratified by high-income and low to middle-
income countries) and CDC controls without Down Syndrome.









<1 year 157 (27.3) 14 (4.3) 6 (5.4) 7 (3.4)
1 year 31 (5.4) 17 (4.9) 8 (7.1) 9 (4.4)
2–4 years 50 (8.7) 43 (13.1) 20 (17.9) 20 (9.7)
5–11 years 97 (16.8) 119 (36.3) 49 (43.8) 68 (33.0)
12–17 years 241 (41.8) 136 (41.5) 29 (25.9) 102 (49.5)
Gender, n (%)
Male 292 (50.7) 155 (47.4) 45 (40.2) 106 (51.4)
Female 284 (49.3) 172 (52.6) 67 (59.8) 99 (48.1)
Table A4. Signs and symptoms related to COVID-19 in individuals with Down Syndrome comparing hospitalised with
non-hospitalised patients, stratified by high-income and low to middle-income countries.















Cough, n (%) 59 (67.0) 88 19 (82.6) 23 0.202 38 (36.5) 104 47 (47.0) 100 0.156
Fever, n (%) 55 (62.5) 88 21 (91.3) 23 0.010 64 (61.5) 104 95 (95.0) 100 <0.001
Nasal congestion,
n (%) 49 (55.7) 88 13 (56.5) 23 1 63 (60.6) 104 67 (67.0) 100 0.383
Shortness of
breath, n (%) 25 (28.4) 88 18 (78.3) 23 <0.001 39 (37.5) 104 56 (56.0) 100 0.011
Abdominal pain,
n (%) 18 (20.5) 88 3 (13.0) 23 0.557 13 (12.5) 104 20 (20.0) 100 0.183
Vomiting/nausea,
n (%) 17 (19.3) 88 3 (13.0) 23 0.059 10 (9.6) 104 20 (20.0) 100 0.047
Diarrhoea, n (%) 30 (34.1) 88 6 (26.1) 23 0.618 15 (14.4) 104 12 (12.0) 100 0.682
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Table A5. Data entered into the database during a later phase of the pandemic (22 October to 2 August 2021). T21RS study
characteristics grouped by hospital admission.
Overall Not Hospitalised Hospitalised
n 133 100 25
Additional information through follow-up (%) 12 (9.0) 11 (11.0) 1 (4.0)
Country (%)
India 34 (25.8) 23 (23.0) 7 (29.2)
Brazil 24 (18.2) 20 (20.0) 3 (12.5)
United Kingdom 6 (4.5) 5 (5.0) 1 (4.2)
United States 17 (12.9) 16 (16.0) 1 (4.2)
Spain 9 (6.8) 7 (7.0) 0 (0.0)
other 42 (31.8) 29 (29.0) 12 (50.0)
Age (mean (SD)) 9.04 (5.24) 9.32 (5.10) 7.60 (6.28)
Male (%) 72 (54.1) 51 (51.0) 15 (60.0)
Ethnicity (%)
South Asian 33 (24.8) 22 (22.0) 7 (28.0)
White 64 (48.1) 56 (56.0) 5 (20.0)
Latin American 15 (11.3) 12 (12.0) 2 (8.0)
Black 2 (1.5) 0 (0.0) 2 (8.0)
Arab 3 (2.3) 1 (1.0) 2 (8.0)
West Asian 3 (2.3) 2 (2.0) 1 (4.0)
Admixed — — —
Unknown 13 (9.8) 7 (7.0) 6 (24.0)
Living situation (%)
Living at home with family 126 (99.2) 95 (99.0) 23 (100)
Living alone with support 1 (0.8) 1 (1.0) 0 (0)
Small group home with support 0 (0) 0 (0) 0 (0)
Residential care facility 0 (0) 0 (0) 0 (0)
Other 0 (0) 0 (0) 0 (0)
Type of trisomy 21 (%)
Full/standard 121 (94.5) 91 (93.8) 23 (100.0)
Mosaic 4 (3.1) 3 (3.1) 0 (0.0)
Partial trisomy 0 (0) 0 (0) 0 (0)
Translocation 3 (2.3) 3 (3.1) 0 (0.0)
Level of intellectual disability (%)
Borderline/normal/mild 27 (24.1) 17 (19.8) 7 (38.9)
Moderate 72 (64.3) 58 (67.4) 10 (55.6)
Severe/Profound 13 (11.6) 11 (12.8) 1 (5.6)
Admitted to hospital (%) 25 (20.0) 0 (0.0) 25 (100.0)
Days in hospital (mean (SD)) 22.39 (42.18) NA 22.39 (42.18)
Admitted to ICU (%) 13 (52.0) 0 (0.0) 13 (52.0)
Days in ICU (mean (SD)) 16.73 (24.82) NA 16.73 (24.82)
Mechanical ventilation (%) 7 (10.4) 0 (0.0) 7 (28.0)
Clinical situation at last evaluation (%)
Currently in hospital with symptoms 0 (0) 0 (0) 0 (0)
Died 1 (0.8) 0 (0.0) 1 (4.2)
Not currently in hospital but with symptoms 15 (11.5) 10 (10.0) 3 (12.5)
Other 4 (3.1) 2 (2.0) 2 (8.3)
Recovered from COVID-19 89 (67.9) 67 (67.0) 18 (75.0)
Tested positive but still no symptoms 22 (16.8) 21 (21.0) 0 (0.0)
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Table A6. Data entered into the database during a later phase of the pandemic (October 22 to August 2, 2021). Medical
complications among hospitalised individuals with and without Down Syndrome stratified by high-income and low to
middle-income countries.
Shortness of Breath OR, (CI) Hospitalised OR, (CI) ARDS OR, (CI)
Age (per 5 years) 1.31 (1.05–1.63) 1.75 (1.37–2.23) 2.29 (1.26–4.15)
Male 0.81 (0.52–1.27) 1.45 (0.90–2.34) 2.44 (0.91–6.55)
Level of ID:
borderline/normal/mild (ref) 1 (1–1) 1 (1–1) 1 (1–1)
Level of ID: moderate 1.20 (0.63–2.30) 0.95 (0.46–1.93) 1.40 (0.28–6.91)
Level of ID: severe/profound 0.83 (0.28–2.42) 1.94 (0.57–6.55) 2.68 (0.36–19.9)
Number of comorbidities (per
increase of 3) 0.53 (0.14–2.05) 1.48 (0.96–2.28) 1.82 (0.84–3.97)
Obesity 0.81 (0.52–1.27) 2.27 (1.12–4.59) 2.14 (0.58–7.91)
Thyroid disorder 0.74 (0.42–1.29) 1.19 (0.64–2.22) 3.40 (1.03–11.9)
Seizures/epilepsy 0.92 (0.44–1.92) 3.97 (1.65–9.58) 2.10 (0.58–7.66)
Obstructive sleep apnea 0.77 (0.44–1.36) 0.96 (0.52–1.76) 0.67 (0.19–2.40)
Gastroesophageal reflux 0.43 (0.24–0.79) 1.00 (0.53–1.87) 0.78 (0.18–3.37)
Congenital Heart Defect 0.72 (0.44–1.18) 1.39 (0.81–2.42) 0.52 (0.18–1.54)
Behavioural and psychiatric
condition 0.81 (0.52–1.27) 1.29 (0.65–2.55) 1.22 (0.94–1.58)
Chronic Lung Disease 1.47 (0.85–2.56) 1.02 (0.56–1.87) 1.31 (0.40–4.24)
Associations with age and gender were adjusted for the data source (caregiver versus clinician survey), and associations with living
situation, level of IDD, and comorbidities were adjusted for age, gender, data source, and country of residence. Abbreviations: IDD,
intellectual and developmental disabilities; ref, reference category.
Table A7. Comorbidities reported by the T21RS study.
Overall Patients withShortness of Breath Hospitalised Patients Patients with ARDS
n 328 259 127 20
Obesity 65 (23.0) 37 (29.4) 41 (38.7) 9 (56.3)
Thyroid disorder 93 (28.4) 34 (26.0) 34 (31.2) 9 (56.3)
Seizures/epilepsy 38 (13.1) 19 (14.8) 28 (25.5) 6 (37.5)
Obstructive sleep
apnea 100 (35.5) 45 (36.3) 42 (39.3) 4 (25.0)
Gastroesophageal
reflux 87 (31.4) 35 (28.0) 36 (34.3) 3 (21.4)
Congenital Heart
Defect 149 (47.5) 57 (42.9) 61 (51.7) 8 (42.1)
Behavioural and
psychiatric condition 103 (33.6) 52 (38.8) 60 (52.6) 9 (52.9)
Chronic Lung Disease 103 (36.5) 58 (46.0) 48 (44.0) 9 (52.9)
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Table A8. Risk factors associated with adverse outcomes of COVID-19 in children with Down Syndrome. Associations with
shortness of breath, hospitalisation, and acute respiratory distress. Patients with Down syndrome from the T21RS survey
estimated in adjusted logistic regression models (odds ratios (OR) and 95% confidence intervals (95%-CI)).
Shortness of Breath OR, (CI) Hospitalised OR, (CI) ARDS OR, (CI)
Age (per 5 years) 1.31 (1.05–1.63) 1.75 (1.37–2.23) 2.29 (1.26–4.15)
Male 0.81 (0.52–1.27) 1.45 (0.90–2.34) 2.44 (0.91–6.55)
Level of ID:
borderline/normal/mild (ref) 1 (1–1) 1 (1–1) 1 (1–1)
Level of ID: moderate 1.20 (0.63–2.30) 0.95 (0.46–1.93) 1.40 (0.28–6.91)
Level of ID: severe/profound 0.83 (0.28–2.42) 1.94 (0.57–6.55) 2.68 (0.36–19.9)
Number of comorbidities (per
increase of 3) 0.53 (0.14–2.05) 1.48 (0.96–2.28) 1.82 (0.84–3.97)
Obesity 0.81 (0.52–1.27) 2.27 (1.12–4.59) 2.14 (0.58–7.91)
Thyroid disorder 0.74 (0.42–1.29) 1.19 (0.64–2.22) 3.40 (1.03–11.9)
Seizures/epilepsy 0.92 (0.44–1.92) 3.97 (1.65–9.58) 2.10 (0.58–7.66)
Obstructive sleep apnea 0.77 (0.44–1.36) 0.96 (0.52–1.76) 0.67 (0.19–2.40)
Gastroesophageal reflux 0.43 (0.24–0.79) 1.00 (0.53–1.87) 0.78 (0.18–3.37)
Congenital Heart Defect 0.72 (0.44–1.18) 1.39 (0.81–2.42) 0.52 (0.18–1.54)
Behavioural and psychiatric
condition 0.81 (0.52–1.27) 1.29 (0.65–2.55) 1.22 (0.94–1.58)
Chronic Lung Disease 1.47 (0.85–2.56) 1.02 (0.56–1.87) 1.31 (0.40–4.24)
Associations with age and gender were adjusted for the data source (caregiver versus clinician survey) and associations with living situation,
level of IDD and comorbidities were adjusted for age, gender, data source and country of residence. Abbreviations: IDD, intellectual and
developmental disabilities; ref, reference category.
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